Drug Profile
Eltrombopag - 3SBio
Alternative Names: SSS 20Latest Information Update: 18 Nov 2021
Price :
$50
*
At a glance
- Originator 3SBio
- Class Antianaemics; Antineoplastics; Benzoates; Biphenyl compounds; Carboxylic acids; Hydrazines; Pyrazoles; Radioprotectives; Small molecules
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Idiopathic thrombocytopenic purpura
Most Recent Events
- 23 Apr 2020 Phase-II clinical trials in Idiopathic thrombocytopenic purpura in China (PO), prior to April 2020 (3SBio pipeline, April 2020)
- 22 Apr 2020 Phase-I development is ongoing in China (3SBio pipeline, April 2020)
- 28 Oct 2019 No recent reports of development identified for phase-I development in Idiopathic thrombocytopenic purpura in China (PO)